Merck reports Q3 2026 earnings beat and raises 2026 revenue and EPS outlook
+2 new sources since this summary was written
Merck announced third‑quarter 2026 results with GAAP EPS of $2.04 and non‑GAAP EPS of $2.49, both including a $0.12 per share one‑time charge. Revenue reached $18.1 billion, driven by Keytruda sales of $8.6 billion (up 6%) and Winrevair sales of $694 million (up 93%). The company lifted its full‑year 2026 revenue guidance to $66.8‑$67.3 billion and its adjusted EPS guidance to $2.77‑$2.82 per share.
Why it matters
The raised guidance expands the earnings target for the year, increasing the expected cash flow and potential dividend capacity for shareholders (the company’s release states the new EPS range). The higher revenue outlook reflects stronger product performance, which may support a higher valuation for the stock.
Key facts
- 1GAAP EPS for Q3 2026 was $2.04 and non‑GAAP EPS was $2.49, each including a $0.12 per share one‑time charge. merck.com
- 2Total worldwide sales for Q3 2026 were $18.1 billion, a 5% increase year‑over‑year. sec.gov
- 3Keytruda/Keytruda Qlex sales were $8.6 billion, up 6% YoY. sec.gov
- 4Winrevair sales were $694 million, up 93% YoY. sec.gov
- 5Full‑year 2026 revenue guidance was narrowed to $66.8 billion‑$67.3 billion. sec.gov
- 6Adjusted EPS guidance for 2026 was raised to $2.77‑$2.82 per share. sec.gov
Summary written by AlphAI AI Desk from 20 of 21 sources. Not investment advice. Figures are as stated by the linked sources.